Ethical issues in implementation research: a discussion of the problems in achieving informed consent by Hutton JL et al.
BioMed CentralImplementation Science
ssOpen AcceDebate
Ethical issues in implementation research: a discussion of the 
problems in achieving informed consent
Jane L Hutton*1, Martin P Eccles2 and Jeremy M Grimshaw3
Address: 1Department of Statistics, University of Warwick, Coventry, CV4 7AL, UK, 2Institute of Health and Society, University of Newcastle, 
Newcastle upon Tyne, NE2 4AA, UK and 3Clinical Epidemiology Programme, Ottawa Health Research Institute, Ottawa, Canada
Email: Jane L Hutton* - J.L.Hutton@warwick.ac.uk; Martin P Eccles - martin.eccles@ncl.ac.uk; Jeremy M Grimshaw - jgrimshaw@ohri.ca
* Corresponding author    
Abstract
Background: Improved quality of care is a policy objective of health care systems around the
world. Implementation research is the scientific study of methods to promote the systematic
uptake of clinical research findings into routine clinical practice, and hence to reduce inappropriate
care. It includes the study of influences on healthcare professionals' behaviour and methods to
enable them to use research findings more effectively. Cluster randomized trials represent the
optimal design for evaluating the effectiveness of implementation strategies. Various codes of
medical ethics, such as the Nuremberg Code and the Declaration of Helsinki inform medical
research, but their relevance to cluster randomised trials in implementation research is unclear.
This paper discusses the applicability of various ethical codes to obtaining consent in cluster trials
in implementation research.
Discussion: The appropriate application of biomedical codes to implementation research is not
obvious. Discussion of the nature and practice of informed consent in implementation research
cluster trials must consider the levels at which consent can be sought, and for what purpose it can
be sought. The level at which an intervention is delivered can render the idea of patient level
consent meaningless. Careful consideration of the ownership of information, and rights of access
to and exploitation of data is required. For health care professionals and organizations, there is a
balance between clinical freedom and responsibility to participate in research.
Summary: While ethical justification for clinical trials relies heavily on individual consent, for
implementation research aspects of distributive justice, economics, and political philosophy
underlie the debate. Societies may need to trade off decisions on the choice between individualized
consent and valid implementation research. We suggest that social sciences codes could usefully
inform the consideration of implementation research by members of Research Ethics Committees.
Background
Improved quality of care is a policy objective of health
care systems around the world. Research findings are
sometimes implemented by helping professionals to
acquire skills or knowledge, sometimes by making sys-
tems changes within health care organisations, and some-
times by legislation which restricts or controls practice.
Over the past decade, health care systems have invested
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and associated quality improvement interventions [1].
However, these efforts have had variable success [2].
Implementation research is the scientific study of meth-
ods to promote the systematic uptake of clinical research
findings into routine clinical practice, and hence to reduce
inappropriate care [3]. It includes the study of influences
on the behaviour of health-care professionals and health
care organisations. The emphasis is generally on how
treatments can be delivered effectively, rather than on the
measuring the difference an idealised treatment makes.
Experimental studies that use cluster randomised designs
are generally more appropriate for evaluating interven-
tions in implementation research than individual patient
randomised controlled trials [4]. Cluster randomized tri-
als randomize an intact social unit (cluster) to an inter-
vention and collect data from individuals within that
social unit. In implementation research, a cluster may be
defined as an individual health care professional, a family
practice, a hospital department, or a hospital, and data are
commonly collected on patients cared for in the cluster.
Cluster randomized trials are commonly undertaken to
minimize the risk of contamination that could occur in a
patient randomized trial, if the care of control patients
was influenced by the experience of the health care profes-
sional providing care to experimental patients [4]. Various
codes of medical ethics, such as the Nuremberg Code [5]
(see text below) and the Declaration of Helsinki [6]
inform medical research. We have previously examined
their applicability to cluster randomized trials in general
[7], but their application to cluster randomised trials in
implementation research is not obvious.
Key ethical considerations: The Nuremberg code
1. Voluntary consent of the human subject is absolutely essen-
tial. Ascertaining the quality of the consent rests upon each
individual: responsibility which may not be delegated.
2. The experiment should ... yield fruitful results for the good of
society.
3. Anticipated results must be justified by background knowl-
edge.
4. Avoid all unnecessary physical and mental suffering and
injury.
5. Not conducted if a priori reason to believe death or disability
will occur.
6. Degree of risk taken to be balanced by the humanitarian
importance.
7. Proper preparations should be made to protect the experi-
mental subject.
8. Only conducted by scientifically qualified persons.
9. Subject should be at liberty to end the experiment.
10. Early stopping of experiment if risk of injury, disability,
death.
The primary ethical requirement of consent (central to sta-
tistical and biomedical codes of conduct [8-10]) raises
particular issues for cluster randomised designs [7,11].
Examples of three cluster randomized trials in implemen-
tation research are described in the text below.
The NEXUS Trial [12]
This study evaluated the effectiveness of audit and feedback and
educational reminder messages to implement the UK Royal
College of Radiologists' guidelines for lumber spine and knee x-
ray in UK general practices. The study was undertaken in six
radiology departments and the 247 general practices that they
served. The study design was a before-and-after pragmatic clus-
ter randomised controlled trial using a 2 × 2 factorial design. A
randomly chosen subset of general practice patient records
(paper and computerised) were examined to assess concordance
with criteria derived from the guidelines. The effect of educa-
tional reminder messages (expressed as x-ray requests per
1,000 patients) was an absolute change of -1.53 (95% CI: -
2.5, -0.57) lumbar spine requests and of 1.61 (95% CI: -2.6,
-0.62) knee x-ray requests, relative reductions of approximately
20%. Similarly, the effect of audit and feedback was an abso-
lute change of -0.07 (95% CI: -1.3, 0.9) lumbar spine x-rays
requests and an absolute change of -0.04 (95% CI: -0.95,
1.03) for knee x-rays requests, relative reductions of about 1%.
None of the differences in concordance between groups were
statistically significant.
The COGENT (Computerised Guidelines Evaluation in the 
North of England) Trial [13]
This was a before-and-after cluster randomised controlled trial,
which used a two by two incomplete block design to evaluate the
use of computerised decision support (CDSS) to implement
clinical guidelines for the primary care management of two con-
ditions: asthma in adults and angina. Practices eligible to par-
ticipate in the study were those with one of two computing
systems, and with at least 50% of the general practitioners
reporting use of their practice computer system to view clinical
data and for acute prescribing. Process of care data were col-
lected in two ways: by electronic retrieval from the computerised
medical record and by abstraction from paper medical records.
(At the time of the study the majority of general practices had
both electronic and paper records on the same patient.) Patient-
based outcomes were assessed by postal surveys using a range of
generic and condition specific measures administered at threePage 2 of 8
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just before the intervention and approximately a year after the
intervention. There were no significant effects of CDSS on con-
sultation rates, process of care measures (including prescribing)
or any quality of life domain for either condition. Levels of use
of the CDSS were low.
The DREAM Trial [14]
This was an evaluation of the effectiveness and efficiency of an
area-wide 'extended' computerised diabetes register, which
incorporated a full structured recall and management system,
actively involved patients, and included clinical management
prompts to primary care clinicians based on locally-adapted evi-
dence based guidelines. The trial, in 58 general practices in
three Primary Care Trusts in the northeast of England, was a
pragmatic cluster randomised controlled trial with the general
practice as the unit of randomisation. The computerised struc-
tured recall and management system improved care for people
with diabetes. Patients in intervention practices were more
likely to have at least one diabetes appointment recorded (OR
2.00, 95% CI 1.02, 3.91), to have a recording of a foot check
(OR 1.87, 95% CI 1.09, 3.21), have a recording of receiving
dietary advice (OR 2.77, 95% CI 1.22, 6.29), and have a
recording of blood pressure (BP) (OR 2.14, 95% CI 1.06,
4.36). There was no difference in mean HbA1c or BP levels,
but the mean cholesterol level in patients from intervention
practices was significantly lower (-0.15 mmol/l, 95% CI -0.25,
-0.06). There were no differences in patient-reported outcomes,
or in patient-reported use of drugs or uptake of health services.
NHS investigation and treatment costs, and costs to patients
were not significantly increased by the intervention; there were
administrative costs and there may have been an impact of the
intervention on costs within general practice.
The conduct of cluster randomized trials in implementa-
tion research raise a series of questions: What is consent,
and who should give it? What does the freedom to with-
draw from an experiment mean in implementation
research? Indeed, should implementation research be
considered 'biomedical research' for ethical purposes?
Although the use of medical records in research is consid-
ered by the Council for International Organizations of
Medical Sciences [15], these guidelines claim that public
health and other forms of health care research designed to
contribute directly to the health of individuals or commu-
nities can be distinguished from biomedical research. The
Declaration of Helsinki [6] on biomedical research states
that a 'research protocol should always contain a state-
ment of the ethical considerations involved ...'. However,
the ten ethical considerations, listed in the text below, are
not easily translated into the context of implementation
research. While ethical justification for randomised con-
trolled trials relies heavily on the current state of clinical
knowledge and individual consent, for implementation
research aspects of distributive justice, economics and
political philosophy inform the debate, and the ethical
theories of virtue, duty, and utility are important. In this
paper, we discuss the ethical challenges relating to consent
in cluster trials in implementation research.
Discussion
Requirement for consent
Is consent necessary for cluster randomized trials in
implementation research? Seeking consent poses poten-
tial problems, such as causing bias or distress [16,17]. In
the case of behaviour change, interventions, knowledge of
the intervention, or of the existence of a trial could affect
the outcome behaviour. For example, knowing imple-
mentation of guidelines was the aim of a trial might
encourage professionals to study those guidelines and
thus bias the study results. This risk of bias is recognized
in the Declaration of Helsinki (point 26) as a legitimate
scientific reason why one might chose not to seek consent
[6]. Further, providing information particularly under the
Council of the International Organisation of Medical Sci-
ences recommendations to provide information on 26
separate items [15] represents a considerable administra-
tive task, so that it might be attractive to avoid consent.
It may also be legitimate to consider whether consent is
necessary if the risks to the individual patient are minimal
[16,18]. It can be argued that the distinction between
implementation research and service development is
blurred, often small, and that the requirement for ethics
approval may hinder the development of implementation
science. Many service developments that could legiti-
mately be the subject of implementation evaluations are
conducted in service settings without any consideration of
consent for practitioner or patient. A Medline search from
1966 to 2006 on 'natural experiment' in article titles iden-
tified 19 reports of health evaluations. A non-systematic
sample (the three most recent and therefore most likely to
reflect current practice) found no mention of ethical
approval [19-21]. An additional consideration is that the
risks to individual patients are likely to be small if imple-
mentation is based on rigorous evidence of clinical effec-
tiveness, and if the normal ethical duty of the professional
to do the best for their patient overrides any study require-
ments. In contrast, there may be some risks to a health
care professional if they are found to be practicing subop-
timally.
Our experiences in implementation research in the early
1990s suggested that some ethics committees were con-
fused about this. On at least one occasion, an ethics com-
mittee argued that a cluster randomized implementation
research trial did not need to be formally considered by an
ethics committee. However, as implementation research
does incur potential risks for patients and health care pro-
fessionals, and as implementation researchers might notPage 3 of 8
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ethics review should be required. A review of a cluster ran-
domized trial in implementation research should decide
whether the quality of the design and the study team are
adequate [10], as well as the scope and timing of consent.
Indeed, one might argue that service developments
should be subject to some form of ethical review, given
that they pose not dissimilar risks.
Scope and timing of consent
In a patient randomized trial of a treatment, patients are
asked whether they are willing to consent to randomiza-
tion to the treatment or control, and willing to participate
in all other aspects of a trial, such as regular review visits
with their physician, or completion of outcome question-
naires. For cluster randomised trials in implementation
research, it is useful to make distinctions that are often not
explicit in ordinary randomised controlled trials of treat-
ments. In particular, we consider consent to randomiza-
tion and consent for other aspects of the trial at the level
of the cluster and patient separately.
Seeking consent for randomization to intervention and 
control arms
Health care providers and organisations
Consent might be sought from those who are the focus of
an intervention. Professionals will usually be the primary
subjects, and one might seek consent for an intervention
intended to affect them. However, if a health care profes-
sional chooses not to participate in a study, they are in
effect denying their patients the potential benefits of par-
ticipation. Health care providers ought to do the best for
their patients, and have an obligation to improve their
skills and knowledge. This might suggest that they should
have a high threshold for opting out of implementation
research studies. Opting out could be based on the belief
that there are significant risks for their patients, or that the
opportunity costs of participation are substantial and will
be to the detriment of the care of other patients. We (MPE,
JMG) have used different approaches to consenting health
care professionals, often for pragmatic reasons. In the
NEXUS trial [12], we successfully argued that the trial
interventions were the equivalent of low risk service devel-
opments and that the requirement to seek consent from
all potential healthcare professionals may make the
project unfeasible or bias our assessment of the study out-
come. As a result, we informed all general practitioners
within the study areas that there was an ongoing trial but
did not explicitly seek their consent. When the interven-
tions were rolled out, we received fewer than five com-
plaints from over 1,000 general practitioners involved in
the study. Within the COGENT trial [13], we sought con-
sent from one representative doctor within each partici-
pating general practice in the belief that, in this matter,
they represented their whole practice.
Patients
The level at which an intervention is delivered may deter-
mine whether patients can opt in or out [7]. For interven-
tions delivered at the level of the health care professional,
it is unclear whether one could ever reasonably seek con-
sent for randomization to intervention and control arms
from individual patients who may be affected by the trial
interventions. This can render the idea of consent mean-
ingless [7]. It is unclear how far along the chain of respon-
sibilities consent should or can be sought. For example, a
trial to evaluate whether an educational intervention
would improve district nurses' treatment of leg ulcers
might randomise nurses to receive the intervention, or
not. Nurses could be recruited and consented. If more
than one district nurse served an area, patients could be
asked whether they preferred a participating or non-par-
ticipating nurse: although the intervention is not given to
the patients, they might have preferences. In contrast,
evaluation of an intervention to improve outpatient care
might require involvement by hospital managers, consult-
ants, and junior hospital staff. One could argue that con-
sent should be sought from all junior staff – but should
this then extend to all general practitioners who might
refer their patients to be seen in outpatients? If so, then
should the consent of all the patients who might be
referred be sought? Whom one requires to consent will
considerably affect the logistics of a trial. The further along
the chain one goes, the less feasible seeking consent
becomes. For example, the NEXUS trial [12] attempted to
reduce inappropriate lumbar spine x-ray requests; poten-
tially this could affect any patient with current or future
low back pain. It is not possible to seek consent at the time
of randomization from patients who may present with
low back pain in the future. While it might be possible to
seek consent from patients when they present with low
back pain, it is unclear what consent is being sought. Their
general practitioner will already have received the inter-
vention. If a patient decided that they did not want to
receive care influenced by the intervention, how can the
general practitioner minimize the influence of the inter-
vention for that individual patient? If individual patients
in the control arm wished to receive care influenced by the
intervention, they would have to change to a general prac-
titioner in the intervention arm. Such change would con-
taminate the randomization. We argue from our
experience that it is often nonsensical to seek consent
from individual patients to randomization to interven-
tion and control arms. The obligation on professionals, as
stipulated by professional bodies such as the General
Medical Council, to do their best for their patients over-
rides any study obligations and should protect patients
from inappropriate care. Patients are not generally
regarded as having a responsibility to enter randomised
controlled trials [22], although some people regard per-Page 4 of 8
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duty of a citizen [23].
Seeking consent for data collection and other aspects of 
study conduct
Consent might be sought for the use of routinely held data
or for the collection of additional data, with or without
invasive procedures. For patients who are not directly the
subjects of an intervention, one might seek consent to
extract data from their medical records [15,24]. Consent
might be sought at the point at which records are used, or
before any records are used. Not asking consent for access
to records minimises impact on patients, and has been
advocated [11]. For routine information, it is possible to
access data without peoples' knowledge or consent, both
to minimise the impact on patients (Declaration of Hel-
sinki, point 21) and to enhance the validity of data [25].
However, the value of simple information and courtesy to
research subjects should not be overlooked [16,26]. In the
DREAM trial [14], patients had already consented, or were
being consented, to their data being held within the exist-
ing diabetes register. The study involved no extra 'routine'
data collection, and the data extracted for the trial evalua-
tion were anonymised before being sent for analysis; all
data held for analysis was held in accordance with the
Data Protection Act. For the patient-based questionnaire
study, the investigators sought additional patient consent
to complete one survey at the time of sending the first
questionnaire. The three Local Research Ethics Commit-
tees (LRECs) covering the study sites approved the trial on
this basis, although one LREC required 'opt-out' patient
consent to be sought for participation in the trial. Their
stated reason was that, although patients were explicitly
consented to be on the register, the consent letter they had
signed had not specified 'research' as a use to which their
information could be put. The investigators therefore sent
an 'opt out' consent letter to all patients on the register in
that primary care trust site; 477 out of 4577 (10.4%)
patients invited to participate opted out of the trial.
Studies might require subjects to opt-in, or allow them to
opt-out. The potential implications for study feasibility of
requiring individual patient consent for data collection
may be substantial. A quarter of total research funds were
spent on consent processes in one study that achieved
only 50% participation [23]. We believe that the decision
about whether individual patient consent for data collec-
tion should be based on considerations of both risk and
feasibility. If patients are being contacted to complete a
postal survey, then they can clearly be explicitly ask to
complete a consent form (e.g., COGENT used this
method) and thus be consented during this process.
Return of a survey implies implicit consent to provide
data, but in order to post a questionnaire, access to clinical
data is needed to judge eligibility, and a contact address is
required. The patient's clinician could be responsible for
this, but it is a substantial additional task. For use of rou-
tine administrative data in a tightly controlled research
environment across a large population, individual patient
consent might be waived [24].
Proxy consent and coercion
Patients are sometimes deemed incompetent and other
people, designated proxies, are allowed to give consent on
their behalf. A proxy is usually the next of kin or a legally
authorised representative [24]. Proxy consent for profes-
sionals cannot coherently be based on incompetence, but
might be pragmatically necessary for both professionals
and patients. There are many possible proxies who might
give consent: consultant committees, medical directors,
chief executives, individual doctors, or local research eth-
ics committees. Despite proxy consent, there may still be
problems in a situation where there are hierarchies of
proxies. Ethics committees may allow access to patient
records, but general practitioners may subsequently insist
on individual patient consent before allowing access,
from their own concerns for patient privacy or their per-
ceived liability. This lengthens and slows any study [27].
Thus, proxy consent can easily misfire: well intentioned
over-protective proxies go beyond the law, and threaten
public health and epidemiology [25,27-29]. Proxy con-
sent can also have associated inducements or penalties. A
senior person or committee might decide that an imple-
mentation research trial will include a group of profes-
sionals, with disadvantages for those who do not
participate, such as loss of some desired status. Participa-
tion might earn credits for post-graduate education, which
ensures additional funds for individual doctors, providing
an inducement. Inducements might coerce doctors into,
for example, increasing the uptake of vaccinations or
screening. This can lead to patients' being put under pres-
sure. There are restrictions on inducements offered to
patients to participate in randomised controlled trials,
and to doctors to enroll patients. Any degree of coercion
of doctors sits oddly alongside these restrictions. In a
patient randomised trial, a patient's refusal should not be
allowed to damage the doctor-patient relationship. Ide-
ally, this principle would extend to doctor-doctor or doc-
tor-manager relationships. Coerced participants in
implementation research might well produce false results,
and so research such participants is likely to be a waste of
resources, hence unethical. Alternatively, one might argue
that there will always be some healthcare professionals
and patients who will always resist change and resent
enforced education, and that research that includes
resentful participants is therefore usefully pragmatic.
Introducing bias by seeking consent
One might rule that individual informed consent must
always be obtained. Several studies have assessed thePage 5 of 8
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tion. Studies in family practice (USA) or general practice
(UK) settings reported similar active consent rates for
researchers to have access to patients' medical records:
67% and 61% respectively [30,31]. Of those not consent-
ing, the balance between active refusal and non-response
rates differed: 25% and 8% in the USA, compared with
7% and 32% in UK. Worryingly, the USA study showed
significant differences in important clinical characteristics
between the three subgroups. This at least raises the possi-
bility that study participants would not be representative,
thereby limiting the inferences that could be drawn from
the study. Other studies have also demonstrated this phe-
nomenon. In a randomised trial of 'opt-in' versus 'opt-
out' strategies for an observational study of angina that
required clinic attendance, response was defined as
attendance at a clinic [32]. The 'opt-in' response rate was
38%, compared to 50% in the 'opt-out' group; the latter
group were in poorer health. The potential social, scien-
tific, and financial costs of seeking consent are demon-
strated by the hospital-based study in Canada that spent a
quarter of the budget to achieve only 50.6% participation
in a disease register [23]. This study reported substantial
differences between those who consented and those who
did not, such that no general scientific conclusions based
on the consenters would be valid. In the DREAM Trial
[14], 10% of patients declined to participate. Because the
research team had no access to these patients' data, the
impact of their exclusion is unknown. Considering this
evidence, if individual consent is required, then imple-
mentation research that requires access to medical records
should be abandoned because, even with considerable
expenditure on consent, the results of studies are very
likely to be substantially biased and misleading. A possi-
ble solution could be for patients, when they join a prac-
tice, to give a general consent to direct or indirect
participation in implementation research that need not be
renewed for each new implementation research study
[16].
Which ethics?
Ethical theories
There are several important general theories that provide
ways in which ethical questions can be approached [33]:
Aristotelian virtue ethics, Kantian-type deontological eth-
ics, and consequentialist ethics, or closely related utilitar-
ian ethics. A consequentialist ethic would balance the
implication of the informed consent requirement (that
implementation research cannot provide valid results,
and hence opportunities to improve people's health are
lost) with the consequences of not requiring informed
consent. The utilitarian approach would assign probabili-
ties and values to the various outcomes, such as mislead-
ing results or infringement of autonomy, and reach a
semi-quantitative rule. One could justify the informed
consent requirement by a Kantian-type duty: the duty of
the researcher to seek consent is absolute and takes prior-
ity over any duty to act so that knowledge may be gained
and health improved. However, the imperative to decide
our actions by acting in the way in which we would like
others to act would reverse the priorities of potential
patients as research participants: health and knowledge
gain are of wide social value. Professionals should, as a
matter of duty, seek to learn by participation in imple-
mentation research, and contribute to knowledge for
other professionals arising from the results of implemen-
tation research. This professional duty is also consistent
with an Aristotlian ethic of living one's professional life
well.
The dominance of informed consent in biomedical codes
is consistent with a primary focus on autonomy. Comfort-
able, individualist societies that take the existence and rea-
sonable quality of health care staff and facilities for
granted can afford to focus on autonomy. Respect for
autonomy is one principle in a popular scheme for medi-
cal ethics proposed by Beauchamp and Childress [34] that
has four principles. The other three principles are non-
maleficence (do no harm), beneficence (do good), and
justice. If non-maleficence is only concerned with present
patients, the harm caused by ignorance arising from the
failure of implementation research will be treated as irrel-
evant. The benefit lost by preventing research through
informed consent requirements will often be remote from
the present patient. However, it is possible with chronic
conditions that most of the people who will benefit from
the results of particular research are those who are eligible
to participate in that research. Unless 'justice' is inter-
preted to mean substantial responsibility towards other
people, rather than a reasonable chance of getting access
to goods, it will not be able to trump 'autonomy'. A pro-
ponent of autonomy would assert that autonomy, hence
informed consent, is primary, and harm, loss of benefit, or
extensive justice are less important.
Ordinary people can recognise that informed consent can
raise a problem, and that their concerns about confidenti-
ality might be addressed by other means [35]. The Cana-
dian Institutes of Health Research and UK Medical
Research Council guidelines recognize that consent might
render epidemiological research impossible [24]. Aggre-
gate data on populations of patients respects privacy, so
perhaps implementation research that uses aggregate data
should not seek consent from individual patients. The UK
does not require consent [25] for the use of such aggregate
data. However, with aggregate data, patient level effects
cannot be modeled: analysis at the cluster level removes a
potentially important level of explanation and under-
standing.Page 6 of 8
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The Nuremberg Code and the Declaration of Helsinki aim
to protect patients: but they have limited relevance when
subjects are health professionals, and the division of
responsibilities between professionals, patients, and
researchers must be considered. In contrast to the four
principles of Beauchamp and Childress, obligations to
four groups of people form the framework used by the
International Statistical Institute Declaration on Profes-
sional Ethics [13], from which most social science codes
are derived [36-40].
The groups to whom obligations are owed by statisticians
(taken as an example of social scientists) are: society,
funders and employers, colleagues, and subjects. No one
group has priority. Social obligations require statisticians
to consider conflicting interests and guard against misuse
and misinterpretation of statistics, to benefit as large a
community as possible, and to pursue reasonable objec-
tivity. Hence the interests of patients, doctors, and manag-
ers in promoting the uptake of clinical research must all
be recognised, and the study design must facilitate inter-
pretation and generalisation of results. Obligations to
funders or employers require clarity about roles and
responsibilities; transparency of statistical methods; no
pre-emption of outcomes; and safeguarding privileged
information. For example, if a funder of implementation
research insisted on informed consent, a statistician may
have to state that she cannot ensure that there will be data
relevant to the funder's chosen outcome, as well as what
limitations arise from data on a biased subset of people.
Summary
Greater access to well-grounded information benefits
society, so implementation research, which endeavours to
translate improvements in clinical research into improve-
ments in health care, is ethically commendable. Imple-
mentation research should be guided more by the
principles of social science research, with the clinical treat-
ment of patients being governed by ordinary professional
practice. Seeking individual informed consent is not
merely expensive: it may be futile, as those choosing to
respond will almost certainly be unrepresentative, hence
the study results will be biased. In reality, societies may
face a political decision between individual informed con-
sent and implementation research.
While ethical justification for clinical trials relies heavily
on individual consent, for implementation research
aspects of distributive justice, economics, and political
philosophy underlie the debate. These ethical issues have
been thoroughly debated in the social sciences. Biomedi-
cal codes focus on doctor-patient relations, whereas obli-
gations to a variety of interest groups, ownership of
information, rights of access and exploitation of data, and
responsibilities for professional development are
addressed in social science codes. We suggest that social
sciences codes could usefully inform the consideration of
implementation research by members of research ethics
committees. We recommend that training on the particu-
lar features of implementation research be offered to
those on research ethics committees.
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